Literature DB >> 12201585

Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents.

Q G Li1, S R Mog, Y Z Si, D E Kyle, M Gettayacamin, W K Milhous.   

Abstract

The neurotoxicity of beta-arteether (AE) is related to drug accumulation in blood due to slow and prolonged absorption from the intramuscular injection sites. In this efficacy and toxicity study of AE, the traditional sesame oil vehicle was replaced with cremophore to decrease the accumulation and toxicity of AE. Dihydroartemisinin (DQHS), a more toxic and active metabolite of AE, was also analyzed. When administered at a daily dosage of 25 mg/kg for seven days, blood accumulation of AE with sesame oil (AESO) was used had a 7.5-fold higher area under the curve (AUC) (on last versus first day dosing), while AE with cremophore (AECM) had only a 1.8-fold higher AUC. Although the accumulation of AECM was greatly reduced, its total exposure level (46.29 microg x h/ml) was 2.7-fold higher than with AESO (16.92 microg x h/ml) due to a higher bioavailability of AECM (74.5%) compared with AESO (20.3%). Total exposure time (calculated at over the minimal detected neurotoxicity level of 41.32 ng/ml) of AECM was 103 hours during the whole treatment period (192 hours), which was more than one-third (37%) less than with AESO (162 hours). Similar pharmacokinetic results were also shown with the active metabolite, DQHS. Anorexia and gastrointestinal toxicity with AESO were significantly more severe than with AECM (P < 0.001). Histopathologic examination of the brain demonstrated neurotoxic changes; the AESO rat group was significantly more severe than the AECM rat group. The brain injury scores with AECM were mild to moderate (2.3-3.0), and with AESO they were moderate to severe (3.0-4.7) on day 7 and day 10, respectively. In addition, the results of a 50% cure dose (CD50) against Plasmodium berghei in mice were 34.1 mg/kg for AESO and 14.2 mg/kg for AECM, indicating a significant higher efficacy was found in the AECM animals. Toxicity and efficacy of DQHS were also dependent on its exposure time and level, which was the same as its parent drug (AE). In conclusion, following the seven-day treatment in rats, AE and DQHS exposure time and level varied based on the vehicle used. The extension of drug exposure time and the low peak level of AE and DQHS were more associated with severe neurotoxicity and lower antimalarial efficacy, whereas the high level and short exposure time of AE and DQHS resulted in higher efficacy and milder toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12201585     DOI: 10.4269/ajtmh.2002.66.516

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.

Authors:  L Clemmer; Y C Martins; G M Zanini; J A Frangos; L J M Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

2.  Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether.

Authors:  Laurens Manning; Moses Laman; Madhu Page-Sharp; Sam Salman; Ilomo Hwaiwhanje; Namar Morep; Peter Siba; Ivo Mueller; Harin A Karunajeewa; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

3.  Clinical pharmacokinetics of the diastereomers of arteether in healthy volunteers.

Authors:  Sreedharan N Sabarinath; Omkar P Asthana; Sunil K Puri; Kumkum Srivastava; Kunnath P Madhusudanan; Ram C Gupta
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether.

Authors:  Shu-Hua Xiao; Jun-Min Yao; Jürg Utzinger; Yue Cai; Jacques Chollet; Marcel Tanner
Journal:  Parasitol Res       Date:  2003-12-16       Impact factor: 2.289

6.  Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats.

Authors:  Qigui Li; Michael P Kozar; Todd W Shearer; Lisa H Xie; Ai J Lin; Kirsten S Smith; Yuanzheng Si; Lalaine Anova; Jing Zhang; Wilbur K Milhous; Donald R Skillman
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

7.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

8.  Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study.

Authors:  Robert Scott Miller; Qigui Li; Louis R Cantilena; Kevin J Leary; George A Saviolakis; Victor Melendez; Bryan Smith; Peter J Weina
Journal:  Malar J       Date:  2012-08-01       Impact factor: 2.979

9.  Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.

Authors:  Verena I Carrara; Aung P Phyo; Paw Nwee; Ma Soe; Hsar Htoo; Jaruwan Arunkamomkiri; Pratap Singhasivanon; François Nosten
Journal:  Malar J       Date:  2008-11-06       Impact factor: 2.979

10.  Ameliorative Effects of Curcumin on Artesunate-Induced Subchronic Toxicity in Testis of Swiss Albino Male Mice.

Authors:  Ketaki R Desai; Dhrupadsinh K Rajput; Pragnesh B Patel; Hyacinth N Highland
Journal:  Dose Response       Date:  2015-06-26       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.